Small HDL subclasses become cholesterol-poor during postprandial period after a fat diet intake in subjects with high triglyceridemia increases

Clinica Chimica Acta

Volumn 464, Issue , 2017, Pages 98-105

  Quintanilla Cantú, Armando ^a   Peña de la Sancha, Paola ^a   Flores Castillo, Cristobal ^a   Mejía Domínguez, Ana María ^a   Posadas Sánchez, Rosalinda ^a   Pérez Hernández, Nonanzit ^a   Bautista Pérez, Rocío ^a   Enriquez Calderón, Reyna Esmeralda ^b   Juárez Oropeza, Marco Antonio ^b   Fragoso, José Manuel ^a   Vargas Alarcón, Gilberto ^a   Pérez Méndez, Oscar ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Coronary heart disease; HDL subclasses; Hypertriglyceridemia; Hypoalphalipoproteinemia; Lipoprotein metabolism; Metabolic syndrome; Postprandial state

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 2A; HIGH DENSITY LIPOPROTEIN 2B; HIGH DENSITY LIPOPROTEIN 3A; HIGH DENSITY LIPOPROTEIN 3B; HIGH DENSITY LIPOPROTEIN 3C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIA; LIPID BLOOD LEVEL; LIPID DIET; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTPRANDIAL STATE; PRIORITY JOURNAL; ADVERSE EFFECTS; AGED; BLOOD; CHEMISTRY; FEMALE;

ADULT; AGED; CHOLESTEROL; DIET, HIGH-FAT; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84996606599     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.11.018     Document Type: Article

References (40)

1. [1] Tran-Dinh, A., Diallo, D., Delbosc, S., Varela-Perez, L.M., Dang, Q.B., et al. HDL and endothelial protection. Br. J. Pharmacol. 169 (2013), 493–511.
2. [2] Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., et al. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem. 277 (2002), 4301–4308.
3. [3] Navab, M., Reddy, S.T., Van Lenten, B.J., Fogelman, A.M., HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8 (2011), 222–232.
4. [4] Rye, K.A., Barter, P.J., Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim. Biophys. Acta 2012 (1821), 473–480.
5. [5] Rye, K.A., Barter, P.J., Cardioprotective functions of HDLs. J. Lipid Res. 55 (2014), 168–179.
6. [6] Davidson, W.S., Silva, R.A., Chantepie, S., Lagor, W.R., Chapman, M.J., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 870–876.
7. [7] Pérez-Méndez, O., Torres-Tamayo, M., Posadas-Romero, C., Vidaure Garcés, V., Carreón-Torres, E., et al. Abnormal HDL subclasses distribution in overweight children with insulin resistance or type 2 diabetes mellitus. Clin. Chim. Acta 376 (2007), 17–22.
8. [8] Garvey, W.T., Kwon, S., Zheng, D., Shaughnessy, S., Wallace, P., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003), 453–462.
9. [9] Magkos, F., Mohammed, B.S., Mittendorfer, B., Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int. J. Obes. 32 (2008), 1655–1664.
10. [10] Morgan, J., Carey, C., Lincoff, A., Capuzzi, D., High-density lipoprotein subfractions and risk of coronary artery disease. Curr. Atheroscler. Rep. 6 (2004), 359–365.
11. [11] Gan, K.N., Smolen, A., Eckerson, H.W., La Du, B.N., Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 19 (1991), 100–106.
12. [12] Nordestgaard, B.G., Langsted, A., Freiberg, J.J., Nonfasting hyperlipidemia and cardiovascular disease. Curr. Drug Targets 10 (2009), 328–335.
13. [13] Kannel, W.B., Vasan, R.S., Triglycerides as vascular risk factors: new epidemiologic insights. Curr. Opin. Cardiol. 24 (2009), 345–350.
14. [14] Alcala-Diaz, J.F., Delgado-Lista, J., Perez-Martinez, P., Garcia-Rios, A., Marin, C., et al. Hypertriglyceridemia influences the degree of postprandial lipemic response in patients with metabolic syndrome and coronary artery disease: from the CORDIOPREV study. PLoS One, 9, 2014, e96297.
15. [15] Mora, S., Rifai, N., Buring, J.E., Ridker, P.M., Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 118 (2008), 993–1001.
16. [16] Tiihonen, K., Rautonen, N., Alhoniemi, E., Ahotupa, M., Stowell, J., et al. Postprandial triglyceride response in normolipidemic, hyperlipidemic and obese subjects - the influence of polydextrose, a non-digestible carbohydrate. Nutr. J., 14, 2015, 23.
17. [17] Patsch, J.R., Prasad, S., Gotto, A.M. Jr., Bengtsson-Olivecrona, G., Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. J. Clin. Invest. 74 (1984), 2017–2023.
18. [18] Grundy, S.M., Cleeman, J.I., Daniels, S.R., Donato, K.A., Eckel, R.H., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005), 2735–2752.
19. [19] DeLong, D.M., DeLong, E.R., Wood, P.D., Lippel, K., Rifkind, B.M., A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study. JAMA 256 (1986), 2372–2377.
20. [20] Perez-Martinez, P., Alcala-Diaz, J.F., Delgado-Lista, J., Garcia-Rios, A., Gomez-Delgado, F., et al. Metabolic phenotypes of obesity influence triglyceride and inflammation homoeostasis. Eur. J. Clin. Investig. 44 (2014), 1053–1064.
21. [21] Carstensen, M., Thomsen, C., Hermansen, K., Incremental area under response curve more accurately describes the triglyceride response to an oral fat load in both healthy and type 2 diabetic subjects. Metabolism 52 (2003), 1034–1037.
22. [22] Huesca-Gómez, C., Franco, M., Luc, G., Montaño, L.F., Massó, F., et al. Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism 51 (2002), 443–450.
23. [23] Toledo-Ibelles, P., García-Sánchez, C., Avila-Vazzini, N., Carreón-Torres, E., Posadas-Romero, C., et al. Enzymatic assessment of cholesterol on electrophoresis gels for estimating HDL size distribution and plasma concentrations of HDL subclasses. J. Lipid Res. 51 (2010), 1610–1617.
24. [24] Soto-Miranda, E., Carreón-Torres, E., Lorenzo, K., Bazán-Salinas, B., García-Sánchez, C., et al. Shift of high-density lipoprotein size distribution toward large particles in patients with proteinuria. Clin. Chim. Acta 414 (2012), 241–245.
25. [25] García-Sánchez, C., Torres-Tamayo, M., Juárez-Meavepeña, M., López-Osorio, C., Toledo-Ibelles, P., et al. Lipid plasma concentrations of HDL subclases determined by enzymatic staining on polyacrylamide electrophoresis gels in children with metabolic syndrome. Clin. Chim. Acta 412 (2011), 292–298.
26. [26] García-Sánchez, C., Posadas-Romero, C., Posadas-Sánchez, R., Carreón-Torres, E., Rodríguez-Pérez, J.M., et al. Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores. Atherosclerosis 238 (2015), 250–255.
27. [27] van Wijk, J.P., Halkes, C.J., Erkelens, D.W., Castro, C.M., Fasting and daylong triglycerides in obesity with and without type 2 diabetes. Metabolism 52 (2003), 1043–1049.
28. [28] Lairon, D., Lopez-Miranda, J., Williams, C., Methodology for studying postprandial lipid metabolism. Eur. J. Clin. Nutr. 61 (2007), 1145–1161.
29. [29] Noguchi, K., Hirota, M., Miyoshi, T., Tani, Y., Noda, Y., et al. Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp. Ther. Med. 9 (2015), 84–88.
30. [30] Couillard, C., Bergeron, N., Prud'homme, D., Bergeron, J., Tremblay, A., et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 47 (1998), 953–960.
31. [31] Rashid, S., Uffelman, K.D., Lewis, G.F., The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J. Diabetes Complicat. 16 (2002), 24–28.
32. [32] Geluk, C.A., Halkes, C.J., De Jaegere, P.P., Plokker, T.W., Cabezas, M.C., Daytime triglyceridemia in normocholesterolemic patients with premature aterosclerosis and in their first-degree relatives. Metabolism 53 (2004), 49–53.
33. [33] Denimal, D., Nguyen, A., Pais de Barros, J.P., Bouillet, B., Petit, J.M., et al. Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome. Atherosclerosis 246 (2016), 106–114.
34. [34] Moren, X., Lhomme, M., Bulla, A., Sanchez, J.C., Kontush, A., et al. Proteomic and lipidomic analyses of paraoxonase defined high density lipoprotein particles: association of paraoxonase with the anti-coagulant, protein S. Proteomics Clin. Appl. 10 (2016), 230–238.
35. [35] Martínez-Ramírez, M., Madero, M., Vargas-Alarcón, G., Vargas-Barrón, J., Fragoso, J.M., et al. HDL-sphingomyelin reduction after weight loss by an energy-restricted diet is associated with the improvement of lipid profile, blood pressure, and decrease of insulin resistance in overweight/obese patients. Clin. Chim. Acta 454 (2016), 77–81.
36. [36] Pérez-Méndez, Ó., Pacheco, H.G., Martínez-Sánchez, C., Franco, M., HDL-cholesterol in coronary artery disease risk: function or structure?. Clin. Chim. Acta 429 (2014), 111–122.
37. [37] Niesor, E.J., Will Lipidation of ApoA1 through interaction with ABCA1 at the intestinal level affect the protective functions of HDL?. Biology 4 (2015), 17–38.
38. [38] Patsch, J.R., Karlin, J.B., Scott, L.W., Smith, L.C., Gotto, A.M. Jr., Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc. Natl. Acad. Sci. U. S. A. 80 (1983), 1449–1453.
39. [39] Gugliucci, A., Activation of paraoxonase 1 is associated with HDL remodeling ex vivo. Clin. Chim. Acta 429 (2014), 38–45.
40. [40] Gugliucci, A., Menini, T., Paraoxonase 1 and HDL maturation. Clin. Chim. Acta 439 (2015), 5–13.